Compare EPR Properties (EPR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Regeneron Pharmaceuticals Inc — how do they compare? EPR Properties trades at $60 (market cap $4.58B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 17.9× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.22%). Which is the better fit depends on your goals.
| EPR | REGN | |
|---|---|---|
Market Cap | $4.58B | $82.06B |
Sector | Real Estate | Health |
52-Week High | $64.32 | $812.27 |
52-Week Low | $48.71 | $555.51 |
Enterprise Value | $8.09B | $76.77B |
Dividend Yield | 6.22% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $62.20, up 1.4% today, with a neutral technical signal and mixed earnings history including a recent Q2 2026 beat. The company shows strong profitability with a 91.41% gross margin and raised 2026 FFO guidance, supported by a new $1.6 billion credit facility announced on July 20, 2026. Key resistance is at $63, with support at $61.
Outlook is cautiously positive given analyst consensus of $65.30 price target and dividend stability, but risks include declining net income margins and high valuation multiples. Investment appeal hinges on execution of acquisition strategy amid economic sensitivity.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
